- Home
- MYNZ vs APM Comparison
MYNZ vs APM Comparison
Compare MYNZ & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- APM
- Stock Information
- Founded
- MYNZ 2021
- APM 2010
- Country
- MYNZ Germany
- APM United Kingdom
- Employees
- MYNZ N/A
- APM N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- APM Health Care
- Exchange
- MYNZ Nasdaq
- APM Nasdaq
- Market Cap
- MYNZ 7.9M
- APM 6.9M
- IPO Year
- MYNZ 2021
- APM 2018
- Fundamental
- Price
- MYNZ $1.77
- APM $1.39
- Analyst Decision
- MYNZ Buy
- APM
- Analyst Count
- MYNZ 2
- APM 0
- Target Price
- MYNZ $14.00
- APM N/A
- AVG Volume (30 Days)
- MYNZ 180.5K
- APM 189.0K
- Earning Date
- MYNZ 08-26-2025
- APM 08-26-2025
- Dividend Yield
- MYNZ N/A
- APM N/A
- EPS Growth
- MYNZ N/A
- APM N/A
- EPS
- MYNZ N/A
- APM N/A
- Revenue
- MYNZ $893,991.00
- APM N/A
- Revenue This Year
- MYNZ $26.06
- APM N/A
- Revenue Next Year
- MYNZ $4.97
- APM N/A
- P/E Ratio
- MYNZ N/A
- APM N/A
- Revenue Growth
- MYNZ N/A
- APM N/A
- 52 Week Low
- MYNZ $1.30
- APM $0.46
- 52 Week High
- MYNZ $18.40
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- MYNZ 53.56
- APM 49.96
- Support Level
- MYNZ $1.41
- APM $1.21
- Resistance Level
- MYNZ $1.76
- APM $1.47
- Average True Range (ATR)
- MYNZ 0.16
- APM 0.12
- MACD
- MYNZ 0.02
- APM -0.03
- Stochastic Oscillator
- MYNZ 68.12
- APM 35.29
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.